Smithfield Trust Co. cut its position in shares of Allergan PLC. (NYSE:AGN) by 6.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,043 shares of the company’s stock after selling 342 shares during the period. Smithfield Trust Co.’s holdings in Allergan PLC. were worth $1,226,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in AGN. Israel Discount Bank of New York acquired a new stake in shares of Allergan PLC. during the first quarter worth approximately $988,000. Trust Co. of Vermont boosted its stake in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after buying an additional 1,109 shares during the last quarter. Capital Planning Advisors LLC boosted its stake in shares of Allergan PLC. by 79.3% in the first quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock worth $878,000 after buying an additional 1,625 shares during the last quarter. First Long Island Investors LLC acquired a new stake in shares of Allergan PLC. during the first quarter worth approximately $4,826,000. Finally, Excalibur Management Corp acquired a new stake in shares of Allergan PLC. during the first quarter worth approximately $218,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Shares of Allergan PLC. (AGN) opened at 223.58 on Wednesday. The stock’s 50 day moving average is $240.49 and its 200-day moving average is $238.48. The stock has a market cap of $74.74 billion, a price-to-earnings ratio of 6.81 and a beta of 1.16. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the previous year, the company posted $3.35 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.25%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

WARNING: “Allergan PLC. (AGN) Shares Sold by Smithfield Trust Co.” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/30/allergan-plc-agn-shares-sold-by-smithfield-trust-co.html.

A number of equities research analysts recently commented on AGN shares. BidaskClub cut shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Deutsche Bank AG reissued a “buy” rating and issued a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Goldman Sachs Group, Inc. (The) cut shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a research note on Wednesday, May 10th. Royal Bank Of Canada increased their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research note on Wednesday, May 10th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price objective (up from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.